News

The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting

ReNU syndrome is a rare neurodevelopmental disorder that is caused by variants in the RNU4-2 gene. The agreement aims to address an estimated 75% of ReNU syndrome cases.

Approved by both companies’ boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset involved

This integrated service platform is designed to meet growing demand as computational methods increasingly generate large numbers of candidate antibody sequences in a single design cycle. However, the

This combination aims to provide an additional non-opioid pain relief option without the need for prescriptions. The approval introduces a new choice for individuals seeking relief from persistent

The new investment increases BeOne Medicines’ total spend on US manufacturing facilities to exceed $1bn. This expansion will increase the company’s production capacity for its cancer medicines and

Lu AH69593 is an oral, small-molecule agonist of the orexin 2 receptor (OX2R). The compound is currently being studied in a Phase Ib clinical trial focused on patients

As part of the collaboration, Evogene will use its ChemPass AI platform, a computational chemistry system aimed at generative molecular design, to create, optimise, and rank prospective small-molecule

The gene therapy is under investigation in adults living with BAG3 DCM, a genetic condition that leads to progressive heart failure and reduced survival despite existing treatments. AFTX-201